Putnam FL Investment Management Co. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,175 shares of the biopharmaceutical company’s stock, valued at approximately $9,020,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC raised its position in Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after purchasing an additional 416,192 shares during the period. BlackRock Inc. raised its position in Regeneron Pharmaceuticals by 0.7% in the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock valued at $3,039,305,000 after purchasing an additional 41,406 shares during the period. Vanguard Group Inc. raised its position in Regeneron Pharmaceuticals by 2.9% in the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock valued at $2,588,533,000 after purchasing an additional 148,962 shares during the period. Artisan Partners Limited Partnership raised its position in Regeneron Pharmaceuticals by 1.5% in the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock valued at $963,852,000 after purchasing an additional 29,252 shares during the period. Finally, Polen Capital Management LLC raised its position in Regeneron Pharmaceuticals by 7.3% in the second quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock valued at $779,105,000 after purchasing an additional 108,413 shares during the period. 67.80% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “20,175 Shares in Regeneron Pharmaceuticals, Inc. (REGN) Purchased by Putnam FL Investment Management Co.” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/16/20175-shares-in-regeneron-pharmaceuticals-inc-regn-purchased-by-putnam-fl-investment-management-co.html.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up $2.00 on Thursday, reaching $388.30. The company’s stock had a trading volume of 192,645 shares, compared to its average volume of 902,983. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The stock has a market cap of $41,790.00, a P/E ratio of 33.32, a PEG ratio of 1.51 and a beta of 1.56. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm’s revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the business earned $3.13 EPS. analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

A number of equities research analysts have commented on REGN shares. UBS AG restated a “buy” rating and issued a $535.00 target price (up previously from $489.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 4th. Citigroup Inc. lifted their target price on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Bank of America Corporation restated a “buy” rating and issued a $593.00 target price (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Credit Suisse Group restated a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $475.34.

In other news, Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Sanofi bought 166,415 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were acquired at an average cost of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 76,651 shares of company stock valued at $36,285,438. 10.80% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.